Stocks and Investing Stocks and Investing
Thu, February 4, 2021

Andrew Fein Maintained (BIIB) at Strong Buy with Increased Target to $305 on, Feb 4th, 2021


Published on 2024-10-27 15:30:31 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $289 to $305 on, Feb 4th, 2021.

Andrew has made no other calls on BIIB in the last 4 months.



There are 8 other peers that have a rating on BIIB. Out of the 8 peers that are also analyzing BIIB, 6 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $249 on, Thursday, November 19th, 2020
  • Phil Nadeau of "Cowen & Co." Downgraded from Buy to Hold and Held Target at $215 on, Monday, November 9th, 2020
  • Colin Bristow of "UBS" Initiated at Hold and Held Target at $268 on, Wednesday, October 28th, 2020
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $282 on, Tuesday, October 27th, 2020
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $244 on, Thursday, October 22nd, 2020
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $265 on, Tuesday, October 20th, 2020


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Geoff Meacham of "B of A Securities" Downgraded from Hold to Sell and Held Target at $240 on, Monday, November 9th, 2020
  • Steve Chesney of "Atlantic Equities" Downgraded from Hold to Sell and Held Target at $175 on, Monday, November 9th, 2020
Contributing Sources